BNIP3 and breast carcinoma: It promotes leukemic cell transformation and leukemogenesis through inhibiting ATRA (all-trans-retinoic acid)-induced AML (acute myeloid leukemia) cell differentiation and induced malignant characteristics in breast cancer cells by targeting BNIP3 (BCL2 Interacting Protein 3) (64, 65).